Rationale for pertussis booster vaccination throughout life in Europe

The Lancet Infectious Diseases

Volumn 11, Issue 7, 2011, Pages 557-570

  Zepp, Fred ^a   Heininger, Ulrich ^b   Mertsola, Jussi ^c   Bernatowska, Ewa ^d   Guiso, Nicole ^e   Roord, John ^f   Tozzi, Alberto E ^g   Van Damme, Pierre ^h  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY OF TURKU   (Finland)

^d CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^e INSTITUT PASTEUR   (France)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^h UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PERTUSSIS VACCINE;

BRAIN DISEASE; DISEASE SURVEILLANCE; EPIDEMIC; EUROPE; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; MEDICAL PRACTICE; MORBIDITY; MORTALITY; OTITIS MEDIA; PERTUSSIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RIB FRACTURE; SCHOOL HEALTH EDUCATION; SCHOOL HEALTH SERVICE; SINUSITIS; SYNCOPE; URINE INCONTINENCE; VACCINATION; WEIGHT REDUCTION;

ADOLESCENT; ADULT; BORDETELLA PERTUSSIS; EUROPE; HUMANS; IMMUNIZATION, SECONDARY; PERTUSSIS VACCINE; WHOOPING COUGH; YOUNG ADULT;

EID: 79959301243     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70007-X     Document Type: Review

References (116)

1. WHO-recommended standards for surveillance of selected vaccine-preventable diseases 2003, Vaccine Assessment and Monitoring team, Department of Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
2. Wendelboe AM, Van Rie A, Salmaso S, Englund JA Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005, 24:S58-S61.
3. EUVAC-NET pertussis surveillance final report 1998-2002 (accessed Feb 25, 2011). http://www.euvac.net/graphics/euvac/pdf/pertussis1.pdf.
4. EUVAC-NET pertussis surveillance report 2003-2007 EUVAC-NET, (accessed Feb 25, 2011). http://www.euvac.net/graphics/euvac/pdf/pertussis2.pdf.
5. Summary of notifiable diseases-United States, 1998. MMWR Morb Mortal Wkly Rep 1999, 47:1-92. CDC.
6. Summary of notifiable diseases-United States, 1999. MMWR Morb Mortal Wkly Rep 2001, 48:1-101. CDC.
7. Summary of notifiable diseases-United States, 2000. MMWR Morb Mortal Wkly Rep 2002, 49:1-100. CDC.
8. Summary of notifiable diseases-United States, 2001. MMWR Morb Mortal Wkly Rep 2003, 50:1-108. CDC.
9. Summary of notifiable diseases-United States, 2002. MMWR Morb Mortal Wkly Rep 2004, 51:1-84. CDC.
10. Summary of notifiable diseases-United States, 2003. MMWR Morb Mortal Wkly Rep 2005, 52:1-85. CDC.
11. Summary of notifiable diseases-United States, 2004. MMWR Morb Mortal Wkly Rep 2006, 53:1-79. CDC.
12. Summary of notifiable diseases-United States, 2005. MMWR Morb Mortal Wkly Rep 2007, 54:1-92. CDC.
13. Summary of notifiable diseases-United States, 2006. MMWR Morb Mortal Wkly Rep 2008, 55:1-94. CDC.
14. Summary of Notifiable Diseases-United States, 2007. MMWR Morb Mortal Wkly Rep 2009, 56:1-94. CDC.
15. Anderson RM, May RM Immunisation and herd immunity. Lancet 1990, 335:641-645.
16. Wearing HJ, Rohani P Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathog 2009, 5:e1000647.
17. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV Trends in pertussis among infants in the United States, 1980-1999. JAMA 2003, 290:2968-2975.
18. Roush SW, Murphy TV Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007, 298:2155-2163.
19. Pertussis-United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002, 51:73-76.
20. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE Resurgence of pertussis in Europe. Pediatr Infect Dis J 2005, 24:761-765.
21. Cortese MM, Baughman AL, Zhang R, Srivastava PU, Wallace GS Pertussis hospitalizations among infants in the United States, 1993 to 2004. Pediatrics 2008, 121:484-492.
22. Floret D Pediatric deaths due to community-acquired bacterial infection. Survey of French pediatric intensive care units. Arch Pediatr 2001, 8(suppl 4):705S-711S.
23. De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000, 182:174-179.
24. Bonhoeffer J, Bar G, Riffelmann M, Soler M, Heininger U The role of Bordetella infections in patients with acute exacerbation of chronic bronchitis. Infection 2005, 33:13-17.
25. Lee LH, Pichichero ME Costs of illness due to Bordetella pertussis in families. Arch Fam Med 2000, 9:989-996.
26. O'Brien JA, Caro JJ Hospitalization for pertussis: profiles and case costs by age. BMC Infect Dis 2005, 5:57.
27. Ward A, Caro J, Bassinet L, Housset B, O'Brien JA, Guiso N Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France. Infect Control Hosp Epidemiol 2005, 26:288-292.
28. Bonmarin I, Levy-Bruhl D, Baron N, Njamkepo E, Caro V Pertussis surveillance in French hospitals: results from a 10 year period. Euro Surveill 2007, 12:34-38.
29. Bonmarin I, Poujol I, Levy-Bruhl D Nosocomial infections and community clusters of pertussis in France, 2000-2005. Euro Surveill 2007, 12:E11-E12.
30. Carlsson RM, Trollfors B Control of pertussis-lessons learnt from a 10-year surveillance programme in Sweden. Vaccine 2009, 27:5709-5718.
31. Tozzi AE, Pandolfi E, Celentano LP, Massari M, Salmaso S, degli Atti ML Ciofi Comparison of pertussis surveillance systems in Europe. Vaccine 2007, 25:291-297.
32. WHO-recommended surveillance standard of pertussis (accessed May 1, 2010). http://www.who.int/immunization_monitoring/diseases/pertussis_surveillance/en/index.html.
33. Devine MJ, Bellis MA, Tocque K, Syed Q Whooping cough surveillance in the north west of England. Commun Dis Public Health 1998, 1:121-125.
34. Atti ML Ciofi Degli, Salmaso S, Bella A, et al. Pediatric sentinel surveillance of vaccine-preventable diseases in Italy. Pediatr Infect Dis J 2002, 21:763-768.
35. Theodoridou M, Hadjipanagis A, Persianis N, Makri S, Hadjichristodoulou C Pertussis outbreak detected by active surveillance in Cyprus in 2003. Euro Surveill 2007, 12:E11-E12.
36. Gilberg S, Njamkepo E, Du Chatelet IP, et al. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. J Infect Dis 2002, 186:415-418.
37. Lasserre A, Laurent E, Turbelin C, Hanslik T, Blanchon T, Guiso N. Pertussis among adolescents and adults followed in general practice in a regional French sample, in 2008. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); Nice, France; May 4-8, 2010.
38. Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007, 26:293-299.
39. Cherry JD, Grimprel E, Guiso N, Heininger U, Mertsola J Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J 2005, 24:S25-S34.
40. Cherry JD Epidemiology of pertussis. Pediatr Infect Dis J 2006, 25:361-362.
41. Qin X, Galanakis E, Martin ET, Englund JA Multitarget PCR for diagnosis of pertussis and its clinical implications. J Clin Microbiol 2007, 45:506-511.
42. Riffelmann M, von Konig CH Wirsing, Caro V, Guiso N Nucleic acid amplification tests for diagnosis of Bordetella infections. J Clin Microbiol 2005, 43:4925-4929.
43. Caro V, Guiso N, Alberti C, et al. Proficiency program for real-time PCR diagnosis of Bordetella pertussis infections in French hospital laboratories and at the French National Reference Center for Whooping Cough and other Bordetelloses. J Clin Microbiol 2009, 47:3197-3203.
44. Heininger U, Cherry JD, Stehr K Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis 2004, 38:591-594.
45. Simondon F, Iteman I, Preziosi MP, Yam A, Guiso N Evaluation of an immunoglobulin G enzyme-linked immunosorbent assay for pertussis toxin and filamentous hemagglutinin in diagnosis of pertussis in Senegal. Clin Diagn Lab Immunol 1998, 5:130-134.
46. Kosters K, Riffelmann M, Dohrn B, von Konig CH Comparison of five commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussis. Clin Diagn Lab Immunol 2000, 7:422-426.
47. Mertens PL, Stals FS, Steyerberg EW, Richardus JH Sensitivity and specificity of single IgA and IgG antibody concentrations for early diagnosis of pertussis in adults: an evaluation for outbreak management in public health practice. BMC Infect Dis 2007, 7:53.
48. de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 2000, 38:800-806.
49. Litt DJ, Samuel D, Duncan J, Harnden A, George RC, Harrison TG Detection of anti-pertussis toxin IgG in oral fluids for use in diagnosis and surveillance of Bordetella pertussis infection in children and young adults. J Med Microbiol 2006, 55:1223-1228.
50. Jenkinson D Natural course of 500 consecutive cases of whooping cough: a general practice population study. BMJ 1995, 310:299-302.
51. Tozzi AE, Rava L, degli Atti ML Ciofi, Salmaso S Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life. Pediatrics 2003, 112:1069-1075.
52. Yaari E, Yafe-Zimerman Y, Schwartz SB, et al. Clinical manifestations of Bordetella pertussis infection in immunized children and young adults. Chest 1999, 115:1254-1258.
53. Aksakal FN, Coplu N, Ceyhan MN, et al. High incidence of Pertussis among schoolchildren with prolonged cough in Turkey. Tohoku J Exp Med 2007, 211:353-358.
54. de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 2006, 53:106-113.
55. Bamberger E, Lahat N, Gershtein V, et al. Diagnosing pertussis: the role of polymerase chain reaction. Isr Med Assoc J 2005, 7:351-354.
56. Jacquet JM, Begue P, Grimprel E, et al. Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review. Vaccine 2006, 24:2440-2448.
57. Black S, Friedland LR, Ensor K, Weston WM, Howe B, Klein NP Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Pediatr Infect Dis J 2008, 27:341-346.
58. Black S, Friedland LR, Schuind A, Howe B Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years. Vaccine 2006, 24:6163-6171.
59. Jones T Boostrix (GlaxoSmithKline). IDrugs 2005, 8:656-661.
60. Grimprel E, von Sonnenburg F, Sanger R, Abitbol V, Wolter JM, Schuerman LM Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine 2005, 23:3657-3667.
61. Blatter M, Friedland LR, Weston WM, Li P, Howe B Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine 2009, 27:765-772.
62. Zepp F, Knuf M, Habermehl P, Mannhardt-Laakmann W, Howe B, Friedland LR Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr 2006, 149:603-610.
63. Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics 2006, 117:1084-1093.
64. Halperin SA, Smith B, Russell M, et al. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine 2000, 18:1312-1319.
65. Van der Wielen M, Van Damme P, Joossens E, Francois G, Meurice F, Ramalho A A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine 2000, 18:2075-2082.
66. Van Damme P, Burgess M Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults. Vaccine 2004, 22:305-308.
67. Mertsola J, Booy R, He Q, et al. The immunogenicity of repeated administration of reduced-antigen-content dTpa booster vaccine in adults. 6th World Congress of the World Society for Pediatric Infectious Diseases; Buenos Aires, Argentina; Nov 18-22, 2009 (poster 029).
68. Mertsola J, Booy R, Zepp F, et al. The safety of repeated administration of reduced-antigen-content dTpa boosters. 6th World Congress of the World Society for Pediatric Infectious Diseases; Buenos Aires, Argentina; Nov 18-22, 2009 (poster 045).
69. Barreto L, Guasparini R, Meekison W, Noya F, Young L, Mills E Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine 2007, 25:8172-8179.
70. McIntyre PB, Burgess MA, Egan A, Schuerman L, Hoet B Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination. Vaccine 2009, 27:1062-1066.
71. McIntyre PB, Turnbull FM, Egan AM, Burgess MA, Wolter JM, Schuerman LM High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine 2004, 23:380-385.
72. Bailleux F, Coudeville L, Kolenc-Saban A, Bevilacqua J, Barreto L, Andre P Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine 2008, 26:3903-3908.
73. Knuf M, Zepp F, Meyer C, et al. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine 2006, 24:2043-2048.
74. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source?. Pediatr Infect Dis J 2004, 23:985-989.
75. Kowalzik F, Barbosa AP, Fernandes VR, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J 2007, 26:238-242.
76. De Schutter I, Malfroot A, Dab I, et al. Molecular typing of Bordetella pertussis isolates recovered from Belgian children and their household members. Clin Infect Dis 2003, 36:1391-1396.
77. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010, 85:385-400. WHO.
78. Westra TA, de Vries R, Tamminga JJ, Wilschut JC, Sauboin CJ, Postma MJ. Cost-effectiveness of a cocooning immunization strategy against pertussis for the Netherlands. International Society for Pharmacoeconomics and Outcomes Research 12th Annual Congress; Paris, France; Oct 24-27, 2009.
79. Kaml M, Weiskirchner I, Keller M, et al. Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine 2006, 24:6808-6811.
80. Healy CM, Rench MA, Castagnini LA, Baker CJ Pertussis immunization in a high-risk postpartum population. Vaccine 2009, 27:5599-5602.
81. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006, 55:1-37.
82. Impfempfehlungen der Ständigen Impfkommission am Robert Koch-Institut/Stand Juli 2009. Epidem Bull 2009, 30:279-298.
83. Vaccination schedules and recommendations from the "Haut conseil de la santé publique" in France. Bulletin Épidémiologique Hebdomadaire 2009, 16-17:146-176.
84. Coudeville L, van Rie A, Andre P Adult pertussis vaccination strategies and their impact on pertussis in the United States: evaluation of routine and targeted (cocoon) strategies. Epidemiol Infect 2008, 136:604-620.
85. Van Rie A, Hethcote HW Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 2004, 22:3154-3165.
86. Bamberger ES, Srugo I What is new in pertussis?. Eur J Pediatr 2008, 167:133-139.
87. Andrews R, Herceg A, Roberts C Pertussis notifications in Australia, 1991 to 1997. Commun Dis Intell 1997, 21:145-148.
88. Hellenbrand W, Beier D, Jensen E, et al. The epidemiology of pertussis in Germany: past and present. BMC Infect Dis 2009, 9:22.
89. de Greeff SC, Mooi FR, Schellekens JF, de Melker HE Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J 2008, 27:218-223.
90. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55:1-34.
91. National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2008. MMWR Morb Mortal Wkly Rep 2009, 58:997-1001. CDC.
92. Baron S, Njamkepo E, Grimprel E, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 1998, 17:412-418.
93. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999, 28:1230-1237.
94. Gzyl A, Augustynowicz E, Rabczenko D, Gniadek G, Slusarczyk J Pertussis in Poland. Int J Epidemiol 2004, 33:358-365.
95. Kandola K, Lea A, White W, Santos M A comparison of pertussis rates in the Northwest Territories: Pre- and postacellular pertussis vaccine introduction in children and adolescents. Can J Infect Dis Med Microbiol 2005, 16:271-274.
96. Ntezayabo B, De Serres G, Duval B Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 2003, 22:22-27.
97. Greenberg DP Pertussis in adolescents: increasing incidence brings attention to the need for booster immunization of adolescents. Pediatr Infect Dis J 2005, 24:721-728.
98. Pertussis-United States, 2001-2003. MMWR Morb Mortal Wkly Rep 2005, 54:1283-1286.
99. Cherry JD The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005, 115:1422-1427.
100. Purdy KW, Hay JW, Botteman MF, Ward JI Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 2004, 39:20-28.
101. Caro JJ, Getsios D, El-Hadi W, Payne K, O'Brien JA Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J 2005, 24:S75-S82.
102. Halperin SA, Sweet L, Baxendale D, et al. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?. Pediatr Infect Dis J 2006, 25:195-200.
103. FitzSimons D, Vorsters A, Hoppenbrouwers K, Van Damme P Prevention and control of viral hepatitis through adolescent health programmes in Europe. Vaccine 2007, 25:8651-8659.
104. Use of mass Tdap vaccination to control an outbreak of pertussis in a high school-Cook County, Illinois, September 2006-January 2007. MMWR Morb Mortal Wkly Rep 2008, 57:796-799. CDC.
105. Riffelmann M, Littmann M, Hulsse C, O'Brien J, von Konig CH Wirsing Pertussis: incidence, symptoms and costs. Dtsch Med Wochenschr 2006, 131:2829-2834.
106. Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005, 353:1555-1563.
107. Ward JI, Cherry JD, Chang SJ, et al. Bordetella pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis 2006, 43:151-157.
108. Lee GM, Riffelmann M, von Konig CH Wirsing Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine 2008, 26:3673-3679.
109. Beytout J, Launay O, Guiso N, et al. Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Hum Vaccin 2009, 5:315-321.
110. Hoel T, Wolter JM, Schuerman LM Combined diphtheria-tetanus-pertussis vaccine for tetanus-prone wound management in adults. Eur J Emerg Med 2006, 13:67-71.
111. Hak E, Hermens RP, Hoes AW, Verheij TJ, Kuyvenhoven MM, van Essen GA Effectiveness of a co-ordinated nation-wide programme to improve influenza immunisation rates in The Netherlands. Scand J Prim Health Care 2000, 18:237-241.
112. Forsyth KD, Campins-Marti M, Caro J, et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 2004, 39:1802-1809.
113. Forsyth KD, von Konig CH Wirsing, Tan T, Caro J, Plotkin S Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007, 25:2634-2642.
114. Heininger U, Loos K, Lorenz I, Rascher W Compliance with recommended immunizations in adolescents. Eur J Pediatr 2006, 165:671-676.
115. Halperin SA Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States. Pediatr Infect Dis J 2005, 24:S141-S146.
116. Forsyth K, Tan T, von Konig CH, Caro JJ, Plotkin S Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis J 2005, 24:S69-S74.